Elan, Andrx Antitrust Battle Over Naproxen Deal Heads Back To District Court
A federal appeals court has reinstated part of an antitrust challenge to a deal between Irish drug maker Elan and Skyepharma over a generic version of the non-steroidal anti-inflammatory drug Naprelan...To view the full article, register now.
Already a subscriber? Click here to view full article